Clinical trials: Women With Breast Cancer
Breast Neoplasms
A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer
The purpose of this study was to give access to postmenopausal women with estrogen sensitive primary breast cancer to exemestane for the adjuvant treatment of breast cancer after the use of tamoxifen and to collect all serious…
- Trial name
- NCT00649090
- Testing
- exemestane
- Where
- 61 sites in Belgium
- Volunteers
- 1,549 people
- Sponsor
- Pfizer
Hereditary Cancer, Breast Cancer
The DIALOGUE Study: Swiss-Korean Billateral Collaboration
In Hereditary Breast and Ovarian Cancer (HBOC) communication of genetic test results with relatives is essential to cascade testing.
- Conditions
- Hereditary Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- DIALOGUE (NCT04214210)
- Testing
- Adapted Family Gene Toolkit, Targeted intervention
- Where
- 8 sites in Switzerland
- Volunteers
- 128 people
- Sponsor
- University of Basel
Breast Cancer
Art Therapy Intervention for Breast Cancer Patients
As studies continue to debate the effects of quality of life on survival, increased attention is being focused on investigating complementary alternative therapies to boost overall total health in cancer patients .
- Trial name
- NCT01220960
- Testing
- art therapy
- Where
- Canada
- Volunteers
- 64 people
- Sponsor
- Dr. Sarkis Meterissian
Metastatic Cancer, Cancer, Breast
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
Sarcopenia is defined as reduction in muscle mass and function according to the criteria of the European Working Group on Sarcopenia in older people.
- Conditions
- Metastatic Cancer, Cancer, Breast, Cancer Colon, Cancer, Rectum
- Trial name
- SPACE2 (NCT05154474)
- Testing
- Standard
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- Weprom
Oestrogen Receptor Positive Advanced Breast Cancer
An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis
Determine the overall response rate (ORR) at 48 weeks to everolimus (RAD001, 10mg daily p.o.) and exemestane (25mg daily p.o.) treatment in postmenopausal women with oestrogen receptor positive breast cancer who have previous…
- Trial name
- 4EVERUK (NCT01743560)
- Testing
- RAD001, Exemestane
- Where
- 11 sites in United Kingdom
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant
RATIONALE: A walking program may improve the ability to carry out daily activities after donor bone marrow transplant. PURPOSE: This randomized clinical trial is studying a structured walking program to see how well it works…
- Trial name
- NCT00445731
- Testing
- exercise intervention, management of therapy complications, observation
- Volunteers
- 115 people
- Sponsor
- University of Minnesota
Breast Carcinoma
Patient Navigation and Tailored Treatment Planning in Latina Patients With Breast Cancer
This research trial studies how well patient navigation and tailored treatment planning work in Latina patients with breast cancer.
- Trial name
- NCT02483377
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Southern California
Breast Cancer
Patient-centered Communication About Healthy Weight in Early Breast Cancer
Comorbidities in breast cancer survival account for 49% of overall survival difference between black and white women. Many obesity-related comorbidities disproportionately affect black women, therefore pointing to a need to…
- Trial name
- NCT04504201
- Testing
- Focus Group
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
S0029 Docetaxel in Treating Older Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating older women who have metastatic…
- Trial name
- NCT00025493
- Testing
- docetaxel
- Volunteers
- 27 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer, Aromatase Inhibitors
Combined Training on Body Composition of Postmenopausal Women Undergoing Treatment for Breast Cancer
Breast cancer is a multifactorial disease affecting women, and one of the treatments for its healing and survival is hormone therapy.
- Conditions
- Breast Cancer, Aromatase Inhibitors, Postmenopausal
- Trial name
- NCT02804308
- Testing
- Combined Training
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Universidade Estadual Paulista Júlio de Mesquita Filho
Breast Cyst, Breast Cancer Female
M5 vs. M6 Comparison Study With a Sub Study Into the Dielectric Constant of Aspirated Cyst Fluid
The MARIA breast imaging system is a Conformité Européenne (CE)-marked radio-frequency (RF) medical imaging device. The system employs an electromagnetic imaging technique that exploits the dielectric contrast between normal and…
- Trial name
- NCT03771833
- Testing
- MARIA scan
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- Micrima, Ltd.
Breast Cancer, Radiation Toxicity
Whole Breast Irradiation vs Twice Daily vs. Once Daily Accelerated Partial Breast Irradiation
This is a randomized phase III trial in women with invasive carcinoma of the breast with negative axillary nodes treated by Breast Conserving Surgery (BCS).
- Trial name
- NCT03616626
- Testing
- Once Daily APBI, Twice Daily APBI, Whole Breast Irradiation
- Where
- Egypt
- Volunteers
- 91 people
- Sponsor
- National Cancer Institute, Egypt
Adult Solid Neoplasm, Bladder Carcinoma
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
This phase I trial studies the side effects of vaccine therapy and pembrolizumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment, that…
- Conditions
- Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative
- Trial name
- NCT02432963
- Testing
- Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Tamoxifen may fight breast cancer by blocking the use of estrogen. Anastrozole may fight breast cancer by decreasing estrogen production.
- Trial name
- NCT00053898
- Testing
- anastrozole, tamoxifen citrate, Radiation Therapy
- Where
- 740 sites in United States, Canada and 1 more
- Volunteers
- 3,104 people
- Sponsor
- NSABP Foundation Inc
Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
This is a prospective, randomized, open-label, active-controlled study to evaluate the efficacy and safety of Romiplostim N01 plus all-trans retinoic acid (ATRA) compared with Romiplostim N01 alone in adults with persistent…
- Conditions
- Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers, Ovarian Cancer
- Trial name
- N01-A-PICIT-GT (NCT07586826)
- Testing
- Romiplostim N01, All-trans retinoic acid
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Peking University People's Hospital
Breast Cancer
Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer
A study to examine the potential associations between common single nucleotide polymorphisms and pre-cancerous conditions in breast tissue specimens from postmenopausal women.
- Trial name
- NCT00329017
- Testing
- Fine needle aspiration
- Where
- United States
- Sponsor
- Carol Fabian, MD
Endometrial Cancer, Ovarian Cancer
PRO1107 in Patients With Advanced Solid Tumors
This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors.
- Conditions
- Endometrial Cancer, Ovarian Cancer, Triple Negative Breast Cancer, GastroEsophageal Cancer
- Trial name
- NCT06171789
- Testing
- GEN1107
- Where
- 7 sites in United States, China
- Volunteers
- 33 people
- Sponsor
- Genmab
Advance Solid Tumors
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT07229313
- Testing
- KIVU-107
- Where
- 7 sites in United States, Australia
- Volunteers
- 76 people
- Sponsor
- Kivu Bioscience Inc.
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center
Cancer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either…
- Trial name
- NCT04485013
- Testing
- TTX-080, pembrolizumab, cetuximab
- Where
- 41 sites in United States
- Volunteers
- 240 people
- Sponsor
- Tizona Therapeutics, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.